Vaxinano Revenue and Competitors
Estimated Revenue & Valuation
- Vaxinano's estimated annual revenue is currently $2.6M per year.
- Vaxinano's estimated revenue per employee is $155,000
- Vaxinano's total funding is $8M.
Employee Data
- Vaxinano has 17 Employees.
- Vaxinano grew their employee count by 13% last year.
Vaxinano's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Vaccine Development & Bioproduction / Directeur Développement Vaccin & Bioproduction | Reveal Email/Phone |
2 | Responsable laboratoire R&D | Reveal Email/Phone |
3 | Ingénieur recherche/développement | Reveal Email/Phone |
Vaxinano Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.1M | 33 | 0% | $24.6M | N/A |
#2 | $9.8M | 63 | 133% | $22.9M | N/A |
#3 | $15.7M | 101 | 25% | N/A | N/A |
#4 | $11.8M | 76 | 27% | $16.7M | N/A |
#5 | $3.7M | 24 | 100% | $14.9M | N/A |
#6 | $4.5M | 29 | 0% | $49M | N/A |
#7 | $35.5M | 229 | 21% | N/A | N/A |
#8 | $1.6M | 10 | 11% | N/A | N/A |
#9 | $13.6M | 88 | 69% | N/A | N/A |
#10 | $3.4M | 22 | 22% | $30M | N/A |
What Is Vaxinano?
Vaxinano is a clinical-stage biotechnology company, developing a new generation of nasally administered vaccines that are more efficient and faster to deploy to combat infectious diseases and new pandemics. \n\nThe vaccine is based on STELLAR-NP nanoparticles that confer highly stable, adjuvant-free solution for an effective and long-lasting response tot protect against the most difficult pathogens, such as parasites, viruses or bacteria...
keywords:N/A
$8M
Total Funding
17
Number of Employees
$2.6M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Loos
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.3M | 37 | -10% | N/A |
#2 | $12M | 48 | 17% | N/A |